DB15276InvestigationalVaccines
PR1 leukemia peptide vaccine is under investigation in clinical trial NCT00513578 (Vaccine Therapy and GM-CSF in Treating Patients With Low-Risk or Intermediate-Risk Myelodysplastic Syndrome).
- Also known as
- L-VALINE, L-VALYL-L-LEUCYL-L-GLUTAMINYL-L-.ALPHA.-GLUTAMYL-L-LEUCYL-L-ASPARAGINYL-L-VALYL-L-THREONYL- · Nine amino acid polypeptide derived from proteinase 3 · PR-1 · PR1 · PR1 VAC
Resolves to
Compound
What you can answer from here — as of April 23, 2025
Which companies are running trials of PR1 leukemia peptide vaccine, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account